Full generic competition for blockbuster drug Revlimid began on Jan 31, 2026, and generic entry for Pomalyst is expected in Q1 2026. This massive and immediate loss of revenue creates intense pressure to cut costs and reorganize operations to maintain profitability, making the company receptive to efficiency and automation solutions.
Filing excerpt
For Revlimid, in the U.S., certain generic companies have begun marketing generic lenalidomide products pursuant to volume-limited licenses granted as part of litigation settlements. As of January 31, 2026, the licenses are no longer volume-limited.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10krestructuringGet every 10-K signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/c486bdcb-363e-4533-b859-92787e88f8c9 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "c486bdcb-363e-4533-b859-92787e88f8c9",
"signal_type": "sec-10k",
"signal_subtype": "restructuring",
"detected_at": "2026-02-17T06:30:02.078+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "Full generic competition for blockbuster drug Revlimid began on Jan 31, 2026, and generic entry for Pomalyst is expected in Q1 2026. This massive and immediate loss of revenue creates intense pressure to cut costs and reorganize operations to maintain profitability, making the company receptive to efficiency and automation solutions.",
"metrics": {
"timeframe": "current_year"
},
"summary": "BMY faces immediate revenue cliff as Revlimid and Pomalyst lose exclusivity in Q1 2026",
"excerpts": "For Revlimid, in the U.S., certain generic companies have begun marketing generic lenalidomide products pursuant to volume-limited licenses granted as part of litigation settlements. As of January 31, 2026, the licenses are no longer volume-limited.",
"relevance": 1,
"sentiment": "negative",
"confidence": "medium",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Change management needs",
"signal_category": "workforce",
"regions_mentioned": [
"U.S."
]
}
}
curl https://signals.autobound.ai/v1/signals/c486bdcb-363e-4533-b859-92787e88f8c9 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.